According to the organization, the well-being of oral health professionals who provide oral health care and educate future dental professionals is a top priority for ADEA, which believes that the oral health community must continue to set a positive example when it comes to vaccinations.
ADEA's statement comes in the wake of an Executive Order requiring COVID-19 vaccinations for federal employees.
Additionally, a Joint Statement issued by the American Public Health Association and more than four dozen other health care organizations calls for all health care and long-term care employers to require their employees to receive the COVID-19 vaccine.
The Centers for Disease Control and Prevention has more detail on the COVID-19 vaccines and their effectiveness in reducing transmission of the coronavirus.
The American Dental Education Association is The Voice of Dental Education.
Its mission is to lead and support the health professions community in preparing future-ready oral health professionals.
ADEA members include all 78 US and Canadian dental schools, more than 800 allied and advanced dental education programs, more than 50 corporations and approximately 18,000 individuals.
FDA grants priority review for GSK's gepotidacin gonorrhoea indication
GSK to receive USD370m and future royalties in CureVac/BioNTech settlement
FDA lifts pause on Valneva's chikungunya vaccine IXCHIQ for elderly, updates prescribing information
Anixa Biosciences begins US FDA approved IND transfer to support Phase 2 breast cancer vaccine trial
Pfizer and BioNTech receive EU regulatory backing for LP.8.1-adapted COVID-19 vaccine
Sanofi to acquire Vicebio for USD1.15bn to strengthen respiratory vaccine pipeline
Bavarian Nordic chikungunya vaccine enters Health Canada review process
SK bioscience submits IND for Phase 1/2 clinical trial of new influenza vaccine candidate
GC Biopharma secures Vietnamese approval for varicella vaccine BARYCELA
GSK announces submission of RSV vaccine Arexvy for FDA review
PharmaJet signs MOU with Egyptian UPA and EVA Pharma to introduce needle-free vaccine delivery
Centivax raises USD45m to commercialise universal flu vaccine
CyanVac's nasal COVID vaccine shows promise in phase 1 trial
hVIVO supports Cidara Therapeutics' positive Phase 2b influenza study results